<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04698005</url>
  </required_header>
  <id_info>
    <org_study_id>A-20-28</org_study_id>
    <nct_id>NCT04698005</nct_id>
  </id_info>
  <brief_title>Exogenous Ketones for Acutely Decompensated HEart Failure</brief_title>
  <acronym>KADHEF</acronym>
  <official_title>Exogenous Ketones for Acutely Decompensated Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether supplementation of exogenous ketones in patients with severe&#xD;
      left ventricular dysfunction and acutely decompensated heart failure requiring inotropic&#xD;
      therapy would improve the patient's hemodynamics and symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include patients with acutely decompensated chronic heart failure requiring&#xD;
      inotropic therapy for the syndrome of low cardiac output. While being on the inotropic&#xD;
      therapy, the patients will be randomized to oral supplementation of exogenous ketones vs.&#xD;
      placebo, which will be repeatedly administered over 9 hours. The patients will undergo&#xD;
      continuous invasive hemodynamic monitoring by pulmonary artery catheter, repeated laboratory&#xD;
      assessment, and repeated assessment of the severity of symptoms for 24 hours.&#xD;
&#xD;
      Exogenous ketones will be administered orally using monoester 3-OHB concentrate without added&#xD;
      salts (25g 3-OHB in 65ml H.V.M.N Ketone Ester, H.V.M.N, USA or equivalent). The drink will be&#xD;
      administered over 10 mins every 3 hours, 3 times in a row (hour 0, 3, 6).&#xD;
&#xD;
      All patients with K&lt;3.7 mmol/l will receive a continuous infusion of 7.5% potassium until&#xD;
      reach target K levels of 4.0-4.9 mmol /l. Glycemia will be controlled as needed by insulin&#xD;
      and dextrose to maintain glucose concentration of 4 - 12 mmol/l&#xD;
&#xD;
      All patients will receive standard treatment of acute heart failure, including intravenous&#xD;
      diuretics and inotropic therapy. The recommended inotropic therapy will include milrinone 0.5&#xD;
      ug/kg/min, levosimendan 0.1 ug/kg/min up to 25mg without initial bolus, or dobutamine 0.5&#xD;
      ug/kg/min in patients without chronic therapy with beta-blockers.&#xD;
&#xD;
      The severity of symptoms will be self-reported by the patient using 1-10 visual analog scale.&#xD;
&#xD;
      Workflow:&#xD;
&#xD;
        -  Hemodynamic assessment, assessment of ketones concentration: 1-3h before randomization,&#xD;
           0-9h hourly, 16-24h (next morning)&#xD;
&#xD;
        -  Biochemical assessment (renal function, liver enzymes, BNP, hs-TnT) 0h, 9h, 16-24h&#xD;
&#xD;
        -  Assessment of symptoms and Scv02: 0h, 1h, 3h, 9h, 16-24h&#xD;
&#xD;
      Statistical methods:&#xD;
&#xD;
      Each study arm will include 12 patients. The study size was estimated to have power of (1 -&#xD;
      beta) of 0.8 and alpha of 5% for between-group comparison of changes in cardiac index and&#xD;
      stroke volume index by ANOVA and for comparison of the changes in cardiac index and stroke&#xD;
      volume index by paired t-tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomisation 1:1 to active treatment (exogenous ketones) vs. placebo (drinking water of equivalent volume)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The participant and the physician in charge of the participant will be blinded to the given treatment (ketone drink vs. placebo)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum change of stroke volume index</measure>
    <time_frame>Maximum value of stroke volume index measured between hour 1 - 3 of the study protocol at 15-minute intervals</time_frame>
    <description>Maximum change of stroke volume index (ml/m2) between baseline and hour 1 - 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum change of cardiac index</measure>
    <time_frame>Maximum value of cardiac index measured between hour 1 - 3 of the study protocol at 15-minute intervals</time_frame>
    <description>Maximum change of cardiac index (L/m2) between baseline and hour 1 - 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of mean stroke volume index</measure>
    <time_frame>Mean value of stroke volume index measured every 15 minutes during 9 hours of the study protocol</time_frame>
    <description>Difference between baseline stroke volume index and mean stroke volume index (ml/m2) during the study protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of mean cardiac index</measure>
    <time_frame>Mean value of cardiac index measured every 15 minutes during 9 hours of the study protocol</time_frame>
    <description>Difference between baseline cardiac index (L/m2) and mean cardiac index during the study protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in patient/symptoms</measure>
    <time_frame>Symptoms scored at hours 0, 1, 10, 24 and expressed as an area under the curve</time_frame>
    <description>Change in patient-referred symptoms by visual-analog scale (1=unbearable dyspnea, 10=no symptoms)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Acute Heart Failure</condition>
  <condition>Low Cardiac Output Syndrome</condition>
  <condition>Hemodynamic Instability</condition>
  <condition>Ketosis</condition>
  <arm_group>
    <arm_group_label>Supplementation of exogenous ketones</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exogeneous ketones will be administered orally using monoester 3-OHB concentrate without added salts (25g 3-OHB in 65ml H.V.M.N Ketone Ester, H.V.M.N, USA or equivalent). The drink will be administered over 10 mins every 3 hours, 3 times in a row.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>25g Ketone monoester without added salts</intervention_name>
    <description>oral supplementation of ketone monoester</description>
    <arm_group_label>Supplementation of exogenous ketones</arm_group_label>
    <other_name>25g 3-OHB in 65ml, H.V.M.N Ketone Ester, H.V.M.N, USA or equivalent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic heart failure due ischemic or nonischemic cardiomyopathy&#xD;
&#xD;
          -  Acute decompensation of heart failure with the need of inotropes&#xD;
&#xD;
          -  Achievement of relative stabilization on inotropes (INTERMACS class &gt;2)&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;= 35%&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Deteriorating cardiogenic shock with likely need of mechanical circulatory support in&#xD;
             the subsequent 48 hours&#xD;
&#xD;
          -  Chronic kidney disease grade 4 or 5&#xD;
&#xD;
          -  Diabetic ketoacidosis (3-OHB &gt;2mmol/l at baseline)&#xD;
&#xD;
          -  Hemodynamic severe arrhythmias&#xD;
&#xD;
          -  Acute heart failure due to transient triggers (acute coronary syndrome, atrial&#xD;
             fibrillation, infection etc..)&#xD;
&#xD;
          -  Contraindications to invasive hemodynamic monitoring&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marek Sramko, MD, PhD</last_name>
    <phone>+420776246127</phone>
    <email>marek.sramko@ikem.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine (IKEM)</name>
      <address>
        <city>Prague</city>
        <zip>14059</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Sramko, MD, PhD</last_name>
      <phone>+420731682681</phone>
      <email>marek.sramko@ikem.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Clinical and Experimental Medicine</investigator_affiliation>
    <investigator_full_name>Marek Sramko</investigator_full_name>
    <investigator_title>Head of the Department of Acute Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiac Output, Low</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

